Official Release of Achievements

In 2025, Manners Technology, a world‑leading medical device manufacturer, in collaboration with international environmental organisations and multiple dialysis centres, officially launched the RenewPoint Programme, a full‑life‑cycle closed‑loop recycling initiative for AVF needles. For the first time, the programme achieves 100 % material‑level recycling and regeneration of used AVF needles. Discarded 304/316L stainless‑steel needles are processed via specialised techniques and remelted into raw materials meeting medical‑grade standards for manufacturing new medical devices. Pilot project data shows that this system cuts the carbon footprint of AVF needles by 70 %, and extracts over 950 kg of high‑purity stainless steel from each tonne of discarded needles, realising a disruptive transformation from "infectious waste" to "high‑value urban mine".

R&D Background and Clinical Pain Points

Global consumption of AVF needles for haemodialysis is enormous, with annual usage exceeding 1 billion units in China alone. Conventional disposal methods - incineration or landfilling of infectious medical waste after high‑pressure sterilisation - entail severe problems:

  Massive resource waste: AVF needles are made of high‑quality 304/316L stainless steel, which involves high smelting energy consumption and substantial value. Single‑use destruction represents typical "low‑grade disposal of high‑grade resources".

  Secondary environmental pollution: Incineration generates toxic substances such as dioxins and heavy‑metal fly ash; landfilling occupies land resources, while stainless steel is extremely non‑biodegradable.

  High disposal costs: Medical institutions pay substantial fees for medical waste disposal, ultimately passed on to medical insurance funds and patients.

  Gap in recycling technologies: Small‑sized, blood‑contaminated needles with potential pathogen residues deter traditional recycling industries, lacking safe, efficient and large‑scale recycling technical pathways.

Core Technological Innovations

The manufacturer‑led closed‑loop system overcomes three major technical bottlenecks in medical sharps recycling:

   Front‑end intelligent collection and preliminary treatment system: Specialised intelligent sharps collection boxes are designed. Built‑in RFID chips record needle source, batch number, quantity and other information; the box structure prevents needle retrieval after insertion to avoid reuse. Pre‑installed solid chemical disinfectant sachets rupture automatically upon needle insertion, releasing high‑concentration peracetic acid sterilising gas for initial in‑situ disinfection within a sealed space, greatly reducing biological hazards.

  Mid‑stream intensive safety disassembly and deep purification technology: After transportation to central processing centres, collection boxes enter fully automated production lines. Secondary sterilisation is first performed via ultra‑high‑temperature steam sterilisation (134 °C, 30 minutes). Robotic arms then precisely disassemble and separate stainless‑steel cannulas from plastic hubs. Separated steel cannulas proceed to a multi‑stage electrochemical cleaning and acid‑passivation pipeline to completely remove all organic residues and oxide layers on surfaces, restoring metallic luster.

  Back‑end high‑purity melting and regeneration process: Purified cannulas are compressed into ingots and fed into custom‑built vacuum induction melting furnaces. Remelting under vacuum or inert‑gas protection effectively separates and collects trace impurities such as copper and tin. Online spectrometric composition analysis enables precise micro‑adjustment of elements including chromium and nickel, ensuring regenerated molten steel fully meets ASTM A276 standards for 304/316L stainless steel, even achieving lower carbon content (the "L" requirement for 316L).

Mechanism of Action

Integrating physical, chemical and metallurgical effects, this closed‑loop system unifies biosafety and resource recovery:

  Tiered disinfection ensures biosafety: Combined chemical disinfection and moist‑heat sterilisation thoroughly inactivate even hard‑to‑kill bacterial spores and viruses. Gaseous chemical disinfectants penetrate inner needle lumens, compensating for potential dead zones caused by insufficient steam penetration in moist‑heat sterilisation.

  Material separation and purification: Mechanical disassembly achieves high‑purity separation of stainless steel from plastic, a prerequisite for high‑quality subsequent regeneration. Electrochemical cleaning generates massive micro‑hydrogen bubbles on needle surfaces via electrolysis, whose stripping power strongly removes tightly adhered protein and lipid contaminants.

  Vacuum melting removes impurities and maintains purity: Vacuum environments effectively prevent oxidation of molten metal, while low‑boiling‑point impurities such as zinc and lead volatilise and are extracted by utilising differences in element vapour pressure. Non‑volatile impurities are adsorbed and removed via slag refining, yielding highly pure regenerated molten steel.

Efficacy Validation

The RenewPoint Programme conducted a one‑year pilot study across 30 dialysis centres in North China, recycling and processing over 5 million discarded AVF needles.

  Environmental benefit assessment: Third‑party life‑cycle evaluation shows that closed‑loop recycling of each kilogram of AVF needles reduces greenhouse‑gas emissions equivalent to 14 kg of CO₂ and saves 42 kWh of energy compared with conventional incineration.

  Resource recovery rate: Stainless‑steel recycling and reuse rate exceeds 95 %. Authoritative testing confirms regenerated steel features corrosion resistance and mechanical properties (hardness HRC 30–40) identical to virgin materials, fully complying with raw‑material standards for manufacturing new AVF needles.

  Hygiene‑safety verification: Bacterial culture, endotoxin testing and viral nucleic‑acid residue testing of intermediate products and final regenerated steel all return negative results, proving complete elimination of biological contamination risks via the treatment workflow.

  Economic analysis: Despite high initial investment, regenerated steel costs 15–20 % less than virgin steel after scaling‑up. Together with saved medical waste disposal fees, the project is expected to break even within 3–5 years.

R&D Strategy and Philosophy

Manners Technology's disposal strategy stems from the philosophy of Extended Producer Responsibility (EPR). It firmly believes manufacturers are accountable not only for product production and usage, but also for their end‑of‑life management. Its core principle is that waste is resources misplaced, especially for medical devices made of high‑value engineering materials. Forming a cross‑border alliance with metallurgical research institutes and environmental‑technology companies, it deeply integrates medical infection‑control technologies, automated robotics and specialised metallurgical technologies, aiming to open a feasible circular‑economy pathway for high‑value medical metal waste beyond medical plastics.

Future Outlook

Future AVF needle recycling will evolve toward molecular‑level circularity and a Product‑as‑a‑Service (PaaS) model. Manufacturers are developing traceable biodegradable hubs: hubs made from specially formulated bio‑based plastics that degrade rapidly under post‑use conditions to simplify separation processes. A more forward‑looking concept is the material ID tag: microscopic two‑dimensional codes laser‑etched onto each needle to record material composition, production batch and even usage information. Prior to recycling melting, spectrometric sorting automatically classifies stainless‑steel grades (e.g., 304 vs. 316L) to realise more precise "like‑for‑like regeneration". Ultimately, manufacturers may shift to a needle leasing service model: hospitals pay for needle usage, while manufacturers handle supply, recycling and regeneration, transforming single‑use consumables into recyclable assets and fundamentally reshaping business models.